source
- Osivax’s flu vaccine OVX836 misses primary efficacy goal in phase 2b trialOsivax announced that its influenza A vaccine candidate OVX836 failed to meet the primary efficacy endpoint in a phase 2b trial involving 2,850 healthy adults in Europe. The trial showed a vaccine…
- Osivax shifts to combination strategy after Phase 2b flu vaccine setbackOsivax, a French biotech, reported that its lead influenza vaccine candidate did not meet primary endpoints in a Phase 2b study. The trial, which evaluated the vaccine as a standalone product, sho…